Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$211.82 - $248.24 $29,442 - $34,505
-139 Reduced 12.79%
948 $214,000
Q2 2023

Aug 11, 2023

BUY
$205.19 - $232.99 $2,051 - $2,329
10 Added 0.93%
1,087 $239,000
Q1 2023

May 12, 2023

SELL
$212.99 - $276.17 $14,270 - $18,503
-67 Reduced 5.86%
1,077 $241,000
Q4 2022

Feb 13, 2023

BUY
$205.95 - $280.43 $10,297 - $14,021
50 Added 4.57%
1,144 $318,000
Q3 2022

Nov 10, 2022

SELL
$203.3 - $244.17 $87,419 - $104,993
-430 Reduced 28.22%
1,094 $229,000
Q2 2022

Aug 12, 2022

SELL
$174.81 - $241.14 $163,971 - $226,189
-938 Reduced 38.1%
1,524 $359,000
Q1 2022

May 13, 2022

SELL
$166.16 - $213.96 $316,202 - $407,165
-1,903 Reduced 43.6%
2,462 $442,000
Q4 2021

Feb 11, 2022

SELL
$184.32 - $216.08 $591,482 - $693,400
-3,209 Reduced 42.37%
4,365 $943,000
Q3 2021

Nov 12, 2021

SELL
$179.86 - $214.88 $491,917 - $587,696
-2,735 Reduced 26.53%
7,574 $1.4 Million
Q2 2021

Aug 13, 2021

SELL
$170.47 - $211.93 $354,577 - $440,814
-2,080 Reduced 16.79%
10,309 $1.85 Million
Q1 2021

May 14, 2021

BUY
$153.94 - $174.85 $206,587 - $234,648
1,342 Added 12.15%
12,389 $2.07 Million
Q4 2020

Feb 12, 2021

BUY
$101.87 - $151.79 $549,588 - $818,907
5,395 Added 95.45%
11,047 $1.68 Million
Q3 2020

Nov 13, 2020

BUY
$99.9 - $121.13 $564,634 - $684,626
5,652 New
5,652 $571,000
Q1 2020

May 14, 2020

SELL
$79.39 - $115.35 $17,227 - $25,030
-217 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$74.85 - $85.99 $97,679 - $112,216
-1,305 Reduced 85.74%
217 $17,000
Q2 2019

Aug 13, 2019

BUY
$76.06 - $120.81 $99,790 - $158,502
1,312 Added 624.76%
1,522 $119,000
Q1 2019

May 14, 2019

BUY
$107.15 - $126.84 $22,501 - $26,636
210 New
210 $25,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Fort, L.P. Portfolio

Follow Fort, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Fort, L.P. with notifications on news.